A question that’s starting to surface more often in clinics:
“Doctor, I saw this treatment online… should I be on it?”
Recently, I’ve noticed how frequently highly targeted oncology ads—especially around conditions like myeloma—are reaching both clinicians and patients.
From a marketing perspective, it’s a win.
Precision targeting.
Hyper-relevant messaging.
The right information, reaching the right audience.
But inside the consultation room, the story shifts.
Patients are no longer coming in with just symptoms—they’re arriving with opinions, expectations, and sometimes anxiety shaped by what they’ve already seen online.
And that changes the conversation. 
Because oncology isn’t just another specialty.
It carries urgency, vulnerability, and high emotional stakes.
So when ads reach patients before clinical guidance does, awareness can quickly blur into influence.
Not intentionally—but impactfully.
Which raises a deeper question:
Are we truly empowering patients with information—
or shaping perceptions before context, nuance, and individualized care can be applied?
Because in the age of precision medicine, communication has become just as targeted as treatment.
But should it be?
Where do you think the line lies between meaningful patient awareness and subtle overreach in oncology communication?